IQ-AI’s David Smith updates on patents and StoneChecker FDA process
IQ-AI’s David Smith updates on patents and StoneChecker FDA process
David Smith, chief executive of IQ-AI Limited’s (LON:IQAI) operating subsidiaries, spoke to Proactive London’s Andrew Scott about the recent filing of a patent for gadolinium-free magnetic resonance imaging (MRI) scan.